
First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo
The first patient was dosed in the SKYBRIDGE clinical study evaluating peluntamig in combination with the anti-PD-L1 monoclonal antibody Tecentriq (atezolizumab) for extensive-stage small cell lung cancer, large cell neuroendocrine carcinoma of the lung or …